X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CADILA HEALTHCARE - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CADILA HEALTHCARE GLENMARK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 19.9 24.0 82.9% View Chart
P/BV x 3.6 6.0 59.0% View Chart
Dividend Yield % 0.3 0.8 43.5%  

Financials

 GLENMARK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
CADILA HEALTHCARE
Mar-17
GLENMARK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs993460 215.9%   
Low Rs729305 239.1%   
Sales per share (Unadj.) Rs325.592.1 353.4%  
Earnings per share (Unadj.) Rs39.314.8 265.2%  
Cash flow per share (Unadj.) Rs48.718.5 263.3%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.20.8 27.8%  
Book value per share (Unadj.) Rs159.268.0 234.2%  
Shares outstanding (eoy) m282.171,023.74 27.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.2 63.7%   
Avg P/E ratio x21.925.8 84.9%  
P/CF ratio (eoy) x17.720.7 85.5%  
Price / Book Value ratio x5.45.6 96.1%  
Dividend payout %5.121.6 23.6%   
Avg Mkt Cap Rs m242,991391,581 62.1%   
No. of employees `00013.016.9 76.9%   
Total wages/salary Rs m16,40815,002 109.4%   
Avg. sales/employee Rs Th7,083.95,594.5 126.6%   
Avg. wages/employee Rs Th1,265.4890.1 142.2%   
Avg. net profit/employee Rs Th855.1899.9 95.0%   
INCOME DATA
Net Sales Rs m91,85794,295 97.4%  
Other income Rs m3741,286 29.1%   
Total revenues Rs m92,23095,581 96.5%   
Gross profit Rs m20,36719,036 107.0%  
Depreciation Rs m2,6443,750 70.5%   
Interest Rs m2,373450 527.4%   
Profit before tax Rs m15,72416,122 97.5%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-3 26,983.3%   
Tax Rs m3,8271,289 296.9%   
Profit after tax Rs m11,08815,168 73.1%  
Gross profit margin %22.220.2 109.8%  
Effective tax rate %24.38.0 304.4%   
Net profit margin %12.116.1 75.0%  
BALANCE SHEET DATA
Current assets Rs m68,74660,223 114.2%   
Current liabilities Rs m27,02753,058 50.9%   
Net working cap to sales %45.47.6 597.7%  
Current ratio x2.51.1 224.1%  
Inventory Days Days8570 121.7%  
Debtors Days Days9688 108.4%  
Net fixed assets Rs m24,13272,984 33.1%   
Share capital Rs m2821,024 27.6%   
"Free" reserves Rs m44,64368,576 65.1%   
Net worth Rs m44,92569,600 64.5%   
Long term debt Rs m45,36324,684 183.8%   
Total assets Rs m117,639152,207 77.3%  
Interest coverage x7.636.8 20.7%   
Debt to equity ratio x1.00.4 284.7%  
Sales to assets ratio x0.80.6 126.0%   
Return on assets %11.410.3 111.5%  
Return on equity %24.721.8 113.2%  
Return on capital %19.117.9 106.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15221,280 263.9%   
Fx outflow Rs m8,08410,874 74.3%   
Net fx Rs m48,06810,406 461.9%   
CASH FLOW
From Operations Rs m6,57413,495 48.7%  
From Investments Rs m-7,124-29,103 24.5%  
From Financial Activity Rs m5,43223,158 23.5%  
Net Cashflow Rs m1,9927,556 26.4%  

Share Holding

Indian Promoters % 48.3 74.8 64.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.3 83.1%  
FIIs % 34.4 5.9 583.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   56,727 44,069 128.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS